- Home
- EGY vs CRMD Comparison
EGY vs CRMD Comparison
Compare EGY & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGY
- CRMD
- Stock Information
- Founded
- EGY 1985
- CRMD 2006
- Country
- EGY United States
- CRMD United States
- Employees
- EGY N/A
- CRMD N/A
- Industry
- EGY Oil & Gas Production
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- EGY Energy
- CRMD Health Care
- Exchange
- EGY Nasdaq
- CRMD Nasdaq
- Market Cap
- EGY 649.4M
- CRMD 626.8M
- IPO Year
- EGY N/A
- CRMD 2010
- Fundamental
- Price
- EGY $5.26
- CRMD $10.33
- Analyst Decision
- EGY Strong Buy
- CRMD Strong Buy
- Analyst Count
- EGY 1
- CRMD 5
- Target Price
- EGY $8.00
- CRMD $15.20
- AVG Volume (30 Days)
- EGY 810.1K
- CRMD 1.7M
- Earning Date
- EGY 11-11-2024
- CRMD 10-30-2024
- Dividend Yield
- EGY 4.75%
- CRMD N/A
- EPS Growth
- EGY 170.05
- CRMD N/A
- EPS
- EGY 0.86
- CRMD N/A
- Revenue
- EGY $506,421,000.00
- CRMD $12,262,234.00
- Revenue This Year
- EGY $4.66
- CRMD N/A
- Revenue Next Year
- EGY N/A
- CRMD $277.75
- P/E Ratio
- EGY $6.09
- CRMD N/A
- Revenue Growth
- EGY 25.82
- CRMD 41184.20
- 52 Week Low
- EGY $4.03
- CRMD $2.89
- 52 Week High
- EGY $7.51
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- EGY 36.77
- CRMD 47.62
- Support Level
- EGY $5.19
- CRMD $11.27
- Resistance Level
- EGY $5.88
- CRMD $12.40
- Average True Range (ATR)
- EGY 0.20
- CRMD 0.89
- MACD
- EGY -0.01
- CRMD -0.17
- Stochastic Oscillator
- EGY 10.14
- CRMD 20.90
About EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea and Corporate and Other. The company generates maximum revenue from the Gabon segment.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.